HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pascoe offers Iberogast alternative

This article was originally published in OTC Bulletin & The Rose Sheet

Executive Summary

Natural medicines specialist Pascoe Naturmedizin is positioning in the German market its Pascoventral herbal gastrointestinal liquid as a non-celandine alternative to Bayer Consumer Health’s Iberogast, which has been recently hit by controversy in the country.

You may also be interested in...

Bayer Stands By Iberogast As German Court Investigates Manslaughter Case

Bayer's Iberogast is in the spotlight in Germany. According to media reports, a German court is investigating a 2018 Iberogast-related death as a possible case of manslaughter and bodily harm caused by negligence. Bayer is standing behind its product, stating that the death was “most probably” due to an “idiosyncratic reaction.”  

The Quality Lowdown: On Redeploying Inspectors, API Suppliers Thanks To Coronavirus

US investigators fan out to non-China inspection priorities and Secretary Azar talks supply management; warning letters hit record keeping, investigations and basic GMP compliance.

Mallinckrodt's Opioid Resolution Through Generic Unit Bankruptcy May Be 'Test Case'

Mallinckrodt to pay $1.6bn and place its generics unit in bankruptcy under agreement in principle for US global settlement; six states are not on board, including New York, whose suit is still set to go to trial March 20.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts